J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jovanovic, L
Right arrow Articles by Goldstein, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jovanovic, L
Right arrow Articles by Goldstein, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

L Jovanovic, G Dailey 3rd, WC Huang, P Strange, and BJ Goldstein

In this 24-week multicenter, double-blind, randomized, fixed-dose trial, 361 patients having type 2 diabetes received daily preprandial treatment with placebo (n = 75), repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146). By a last-observation carried-forward calculation, repaglinide 1 mg or 4 mg treatment decreased mean fasting plasma glucose (FPG) values (by -47 mg/dL or -49 mg/dL) while the placebo group had increased FPG values (by 19 mg/dL). For the repaglinide treatment groups at the end of the study, changes in HbA1c from baseline values ranged from 1.8 to 1.9 percentage points lower than the placebo group. There were no events of severe hypoglycemia. Nearly all hypoglycemic symptom episodes had blood glucose levels above 45 mg/dL. Repaglinide was well tolerated in a preprandial fixed-dose regimen of 1 mg or 4 mg, assigned without adjustment for clinical parameters.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
S. S Lund, L. Tarnow, M. Frandsen, B. B Nielsen, B. V Hansen, O. Pedersen, H.-H. Parving, and A. A Vaag
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
BMJ, November 9, 2009; 339(nov09_1): b4324 - b4324.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al.
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. Lopez-Garcia, J. Borras, C. Verdu, V.R. Salazar, J. A. Ruiz, J. Sales, M. I. Lucena, and R. J. Andrade
Cholestatic Hepatitis Associated With Repaglinide
Diabetes Care, March 1, 2005; 28(3): 752 - 753.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J.-F. Yale
Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S7 - S10.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. S. Thomsen, D. Chassard, E. Evene, K. K. Nielsen, and M. Jorgensen
Pharmacokinetics of Repaglinide in Healthy Caucasian and Japanese Subjects
J. Clin. Pharmacol., January 1, 2003; 43(1): 23 - 28.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
O. Schmitz, S. Lund, P. H. Andersen, M. Jonler, and N. Porksen
Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes: A randomized double-blind study with repaglinide
Diabetes Care, February 1, 2002; 25(2): 342 - 346.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. E. Inzucchi
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
JAMA, January 16, 2002; 287(3): 360 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. G. Moses, R. Gomis, K. B. Frandsen, J.-L. Schlienger, and I. Dedov
Flexible Meal-Related Dosing With Repaglinide Facilitates Glycemic Control in Therapy-Naive Type 2 Diabetes
Diabetes Care, January 1, 2001; 24(1): 11 - 15.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Clinical Pharmacology